Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
NCT ID: NCT03387137
Last Updated: 2024-12-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
45 participants
INTERVENTIONAL
2017-10-13
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The vaccine will be evaluated in a stepwise fashion beginning in RSV-seropositive children (Group 1), and then in RSV-seronegative infants and children (Group 2). In each group, participants will be randomly assigned to receive a single dose of RSV 6120/∆NS2/1030s vaccine or placebo at study entry (Day 0).
Participants will be enrolled in the study between April 1 and October 31, outside of the RSV season. Group 1 (RSV-seropositive children) will be followed for 28 days. Group 2 (RSV-seronegative infants and children) will remain on study until they complete the post-RSV season visit.
Group 2 participants may participate in an optional second season of RSV surveillance during November to March of the second year following enrollment.
Study visits for all participants may include clinical assessments, blood collection, and nasal washes. Additionally, participants' parents or guardians will be contacted by study staff at various times during the study to monitor participants' health.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: RSV 6120/∆NS2/1030s Vaccine
RSV-seropositive children will receive a single dose of 10\^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
RSV 6120/∆NS2/1030s
Delivered as nose drops
Group 1: Placebo
RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
Placebo
Delivered as nose drops
Group 2: RSV 6120/∆NS2/1030s Vaccine
RSV-seronegative infants and children will receive a single dose of 10\^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
RSV 6120/∆NS2/1030s
Delivered as nose drops
Group 2: Placebo
RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
Placebo
Delivered as nose drops
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSV 6120/∆NS2/1030s
Delivered as nose drops
Placebo
Delivered as nose drops
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Screening serum specimen for RSV neutralizing antibody is obtained within the calendar year of inoculation
* Seropositive for RSV antibody, defined as serum RSV neutralizing antibody titer greater than or equal to 1:40
* Pre-inoculation serum sample for RSV neutralizing antibody testing is obtained no more than 56 days prior to inoculation
* In good health based on review of the medical record, history, and physical examination at the time of inoculation
* Received routine immunizations appropriate for age based on the Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger
* Growing normally for age as demonstrated on a standard growth chart and has a current height and weight above the 3rd percentile for age
* Expected to be available for the duration of the study
* Parent/guardian is willing and able to provide written informed consent
* Greater than or equal to 6 months of age and less than 25 months of age at the time of inoculation
* Screening and pre-inoculation serum specimens for RSV-neutralizing antibody are obtained no more than 42 days prior to inoculation
* Seronegative for RSV antibody, defined as serum RSV-neutralizing antibody titer less than 1:40
* In good health based on review of the medical record, history, and physical examination at the time of inoculation
* Received routine immunizations appropriate for age based on the ACIP Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger
* Growing normally for age as demonstrated on a standard growth chart, AND
* If less than 1 year of age: has a current height and weight above the 5th percentile for age
* If greater than or equal to 1 year of age: has a current height and weight above the 3rd percentile for age
* Expected to be available for the duration of the study
* Parent/guardian is willing and able to provide written informed consent
* RSV-seronegative participants who have completed the initial RSV season surveillance portion of the study and whose parent/guardian is willing and able to provide written informed consent
* Expected to be available during the second year of RSV surveillance
Exclusion Criteria
* Maternal history of positive HIV test
* Evidence of chronic disease
* Known or suspected impairment of immune function
* Bone marrow/solid organ transplant recipient
* Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities
* Suspected or documented developmental disorder, delay, or other developmental problem
* Cardiac abnormality requiring treatment
* Lung disease or reactive airway disease
* More than one episode of wheezing in the first year of life
* Wheezing episode or received bronchodilator therapy within the past 12 months
* Wheezing episode or received bronchodilator therapy after the age of 12 months
* Previous receipt of supplemental oxygen therapy in a home setting
* Previous receipt of an investigational RSV vaccine
* Previous receipt or planned administration of anti-RSV drug (ribavirin) or RSV antibody product including RSV immune globulin (RSV Ig) or RSV monoclonal antibody (RSV mAb)
* Previous receipt of immunoglobulin or any antibody products within the past 6 months
* Previous receipt of any other blood products within the past 6 months
* Previous anaphylactic reaction
* Previous vaccine-associated adverse reaction that was Grade 3 or above
* Known hypersensitivity to any vaccine component
* Member of a household that contains an infant who is less than 12 months of age at the date of inoculation through the 10th day after inoculation
* Member of a household that, at the date of inoculation through the 10th day after inoculation, contains an immunocompromised individual including but not limited to:
* a person who is HIV-infected
* a person who has received chemotherapy within the 12 months prior to enrollment
* a person receiving immunosuppressant agents
* a person living with a solid organ or bone marrow transplant
* Will attend a daycare facility that does not separate children by age and contains an infant who is less than 12 months of age at the date of inoculation through the 10th day after inoculation
* Receipt of any of the following prior to enrollment:
* any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or
* any live vaccine, other than rotavirus vaccine, within the 28 days prior, or
* another investigational vaccine or investigational drug within 28 days prior, or
* salicylate (aspirin) or salicylate-containing products within the past 28 days
* Scheduled administration of any of the following after planned inoculation:
* inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or
* any live vaccine other than rotavirus in the 28 days after, or
* another investigational vaccine or investigational drug in the 28 days after
* Receipt of any of the following medications within 3 days of study enrollment:
* systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or
* intranasal medications, or
* other prescription medications except the permitted concomitant medications listed below:
* Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents.
* Any of the following events at the time of enrollment:
* fever (temporal or rectal temperature of greater than or equal to 100.4°F), or
* upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis) or
* nasal congestion significant enough to interfere with successful inoculation, or
* otitis media
* Born at less than 34 weeks gestation
* Born at less than 37 weeks gestation, and at the date of inoculation less than 1 year of age
* Maternal history of a positive HIV test
* Evidence of chronic disease
* Known or suspected infection or impairment of immunological functions
* Bone marrow/solid organ transplant recipient
* Major congenital malformations, including congenital cleft palate or cytogenetic abnormalities
* Suspected or documented developmental disorder, delay, or other developmental problem
* Cardiac abnormality requiring treatment
* Lung disease or reactive airway disease
* More than one episode of wheezing in the first year of life
* Wheezing episode or received bronchodilator therapy within the past 12 months
* Wheezing episode or received bronchodilator therapy after the age of 12 months
* Previous receipt of supplemental oxygen therapy in a home setting
* Previous receipt of an investigational RSV vaccine
* Previous receipt or planned administration of anti-RSV antibody product including ribavirin, RSV Ig, or RSV mAb
* Previous receipt of immunoglobulin or any antibody products within the past 6 months
* Previous receipt of any blood products within the past 6 months
* Previous anaphylactic reaction
* Previous vaccine-associated adverse reaction that was Grade 3 or above
* Known hypersensitivity to any study product component
* Member of a household that contains an infant who is less than 6 months of age at the date of inoculation through the 28th day after inoculation
* Member of a household that, at the date of inoculation through the 28th day after inoculation, contains an immunocompromised individual including but not limited to:
* a person who is HIV-infected
* a person who has cancer and has received chemotherapy within the 12 months prior to enrollment
* a person living with a solid organ or bone marrow transplant
* Attends a daycare facility that does not separate children by age and contains an infant less than 6 months of age at the date of inoculation through the 28th day after inoculation
* Receipt of any of the following prior to enrollment:
* any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or
* any live vaccine, other than rotavirus vaccine, within the 28 days prior, or
* another investigational vaccine or investigational drug within 28 days prior, or
* salicylate (aspirin) or salicylate-containing products within the past 28 days
* Scheduled administration of any of the following after planned inoculation
* inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or
* any live vaccine other than rotavirus in the 28 days after, or
* another investigational vaccine or investigational drug in the 56 days after
* Receipt of any of the following medications within 3 days of study enrollment:
* systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or
* intranasal medications, or
* other prescription medications except the permitted concomitant medications listed below:
* Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents.
* Any of the following events at the time of enrollment:
* fever (temporal or rectal temperature of greater than or equal to 100.4°F), or
* upper respiratory signs or symptoms (rhinorrhea, cough, or pharyngitis) or
* nasal congestion significant enough to interfere with successful inoculation, or
* otitis media
* Currently enrolled in another RSV study
6 Months
60 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ruth A. Karron, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins Bloomberg School of Public Health (JHSPH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Karron RA, Luongo C, Woods S, Oliva J, Collins PL, Buchholz UJ; RSVPed Team. Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV/6120/DeltaNS2/1030s in RSV-Seronegative Young Children. J Infect Dis. 2024 Feb 14;229(2):346-354. doi: 10.1093/infdis/jiad281.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form: RSV-Seronegative
Document Type: Informed Consent Form: RSV-Seropositive
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIR 322
Identifier Type: -
Identifier Source: org_study_id